The Price–Volume Agreement Program (PVAP) was promulgated in 2007 in South Korea as the first attempt to adjust drug pricing according to total consumption in order to contain drug expenditure. This study was designed to assess the impact of the PVAP on diabetes drug expenditure for a period of a 10-year period (2003–2012) using claims data from the National Health Insurance Service. We estimated a multilevel mixed-effects linear regression model by comparing the level of total monthly diabetes drug expenditure for drugs subject to PVAP and existing drugs after adjusting the average differences in drug expenditure before and after the PVAP. The monthly total expenditure for drugs that were newly listed through the PVAP (negotiation drugs) was 7.03% higher on average compared to that for existing drugs, controlling for the baseline differences in expenditure before and after the PVAP. This increase was observed in all four subgroups of diabetes drugs, including sitagliptin, vildagliptin, exenatide, and others. The growth rate of total diabetes drug expenditure was reduced after the PVAP despite the sustained escalation of expenditure levels, which may imply that the PVAP has the potential to be an effective tool for drug expenditure control in the long term.
Bibliographical noteFunding Information:
We acknowledge research support from National Health Insurance Service (NHIS) in Korea. The lead author (EH) also acknowledges research support from the Korea National Research Foundation (2014R1A1A3A04049984). The funding agencies were not involved in study design, data collection, analysis and interpretation of data, the writing of the report, and in the decision to submit the article for publication.
© 2016 Elsevier Ireland Ltd
All Science Journal Classification (ASJC) codes
- Health Policy